Search clinical trials for: [18F]PI-2620

Total 2802 results

Life Molecular Imaging Ltd

Recruiting

[18F]PI-2620 Phase 3 Histopathological Study

Alzheimer Disease

United States
Life Molecular Imaging SA
Walter Reed National Military Medical Center

Active, not recruiting

Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury

Mild Traumatic Brain Injury

United States
Jae Seung Kim

Completed

Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease

Alzheimer Disease | Mild Cognitive Impairment | Cognitively Normal

Korea, Republic of
Asan Medical Center
Korea Health Industry Development Institute

Completed

Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain

Parkinson Disease | Alzheimer Disease | Healthy Volunteer | Frontotemporal Dementia

Korea, Republic of
Genentech, Inc.

Completed

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

Alzheimer Disease (AD)

United States
University of Southern California
National Institute on Aging (NIA); Northern California Institute of Research... and other collaborators

Recruiting

Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4)

Dementia | Alzheimer Disease | Mild Cognitive Impairment

United States, Canada
Macquarie University, Australia
Life Molecular Imaging GmbH; Omniscient Neurotechnology

Active, not recruiting

Tau And Connectomics In TES Study (TACIT)

Neurodegenerative Diseases | Cognitive Impairment | Head Injury Trauma | Chronic Traumatic Encephalopathy | Traumatic Encephalopathy

Australia
University of Pennsylvania
Yale University

Recruiting

Tau PET Imaging in Opioid Use Disorder

Opioid-Related Disorders

United States
Michael J. Fox Foundation for Parkinson's Research
Institute for Neurodegenerative Disorders

Completed

PPMI Tau PET Imaging

Parkinson Disease

United States
University of Pennsylvania
National Institutes of Health (NIH)

Recruiting

Linking Tau PET to Medial Temporal Lobe Subregions With High Resolution MRI

Mild Cognitive Impairment

United States
University of Colorado, Denver
American College of Radiology

Completed

Preclinical Imaging Biomarkers of Alzheimer's Disease Neuropathology in Young Adults With Youth-onset Diabetes: a Proof-of-concept Study

Diabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Diabetes, Youth Onset

United States
University of North Texas Health Science Center

Enrolling by invitation

Health and Aging Brain Study: Health Disparities Tau Positron Emission Tomography (PET) Scan Study

Alzheimer Disease

United States
University Tunis El Manar

Unknown

Uterine Artery Pulsatility Index and Materno Fetal Outcomes (UADLAB)

Labor Complication

Tunisia
Peking University Third Hospital

Completed

Relationship Between Spinopelvic Parameters and Clinical Symptoms of Low-grade Lumbar Isthmic Spondylolisthesis

Isthmic Spondylolisthesis

China
Merck Sharp & Dohme LLC

Completed

[18F]MK-6240 Positron Emission Tomography (PET) Tracer First-in-Human Validation Study (MK-6240-001)

Alzheimer's Disease | Amnestic Mild Cognitive Impairment
University of Pennsylvania
National Institutes of Health (NIH)

Recruiting

PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620

Alzheimer Disease | Frontotemporal Lobar Degeneration | Cognitively Normal

United States
Spero Therapeutics
Covance

Completed

Study of the Absorption, Metabolism, and Excretion of [14C]-Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) Following a Single Oral Dose in Healthy Male Subjects

Healthy Volunteers

United States
Spero Therapeutics
Clinartis

Completed

Study to Assess the Intrapulmonary Pharmacokinetics of SPR859 by Comparing the Plasma, Epithelial Lining Fluid (ELF), and Alveolar Macrophages (AM) Concentrations Following the Oral Administration of Five Doses of SPR994 in Healthy, Nonsmoking Volunteers

Healthy Volunteers

United States
Spero Therapeutics

Completed

Phase 1 Study of PK and Safety of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Subjects With Various Degrees Of Renal Function

Renal Impairment

United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

Study of PI-88 in Patients With Advanced Melanoma

Melanoma

United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

PI-88 in Hepatocellular Carcinoma After Hepatectomy

Carcinoma, Hepatocellular

Taiwan
Massachusetts General Hospital
Cedars-Sinai Medical Center; ALS Association; The Methodist Hospital Research...

Completed

Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis (TRACK-ALS)

Amyotrophic Lateral Sclerosis (ALS)

United States
Oslo University Hospital

Completed

A Multi-disciplinary Pain Intervention (MUD-PI) for Patients With Chronic Widespread Primary Pain (MUD-PI)

Chronic Pain, Widespread
Amgen

Completed

FIRST - Study of Pegfilgrastim Administered in the First and Subsequent Cycles of Myelosuppressive Chemotherapy

Neutropenia
Peptimmune

Completed

Safety Study of PI-0824 to Treat Pemphigus Vulgaris

Pemphigus Vulgaris

United States
British Columbia Cancer Agency

No longer available

18F-FDOPA PET in Neuroendocrine Tumours

Thyroid Cancer, Medullary | Neuroblastoma | Pheochromocytoma | Carcinoid Tumor | Paraganglioma | Insulinoma

Canada
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Study of Florbetapir (18F) in Japanese Healthy Volunteers

Alzheimer's Disease

Japan
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)

Mild Cognitive Impairment | Alzheimer's Disease

Japan
Avid Radiopharmaceuticals

Completed

The Feasibility of Florbetapir Quantitation in Europe

Alzheimer's Disease

Netherlands
Markus Weber
University Hospital Inselspital, Berne; ETH Zurich

Not yet recruiting

Investigation of Cannabinoid 2-receptor Expression in the Brain and Spine of ALS-patients Compared to Healthy Controls With PET (18F-RoSMALS) (18F-RoSMALS)

Amyotrophic Lateral Sclerosis

Switzerland
Frederick Daniel Grant
Dana-Farber Cancer Institute

Completed

FLT-PET Imaging of Brain Tumors in Children

Brain Neoplasms

United States
Avid Radiopharmaceuticals

Withdrawn

Evaluation of Electronic Florbetapir (18F) Interpretation Training in Japanese Physicians

Alzheimer's Disease

Japan
Spero Therapeutics

Completed

Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects

Healthy Volunteers

United States
Assiut University

Recruiting

Perfusion Index in Assessment of Postoperative Pain in Children.

Postoperative Pain

Egypt
Spero Therapeutics

Completed

A Study to Compare Two Bioanalytical Assays for Tebipenem

Healthy Volunteers

United States
Avid Radiopharmaceuticals
Eli Lilly and Company

Completed

Effectiveness of Florbetapir (18F) PET Imaging in Changing Patient Management and the Relationship Between Scan Status and Cognitive Decline

Alzheimer's Disease

France, Italy, United States
Chang Gung Memorial Hospital

Unknown

Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18F-florbetapir (AV-45) PET Examination (PMPBB3/AV45)

Alzheimer's Disease

Taiwan
Minia University

Recruiting

AS-OCT Evaluation of Iridocorneal Angle of Patients of Angle Closure Glaucoma After Phacoemulsification

Glaucoma, Angle-Closure

Egypt
Mayo Clinic
Blue Earth Diagnostics, Inc

Recruiting

18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain

Metastatic Intracranial Malignant Neoplasm | Recurrent Intracranial Neoplasm

United States
University of California, San Francisco
Avid Radiopharmaceuticals; Alzheimer's Drug Discovery Foundation

Recruiting

Effects of Brain Beta-Amyloid on Postoperative Cognition

Postoperative Cognitive Dysfunction

United States
Tammie L. S. Benzinger, MD, PhD

Recruiting

F 18 T807 Tau PET Imaging of Alzheimer's Disease (T807IND)

Alzheimer Disease

United States
Washington University School of Medicine

Enrolling by invitation

F 18 T807 Tau PET Imaging in Dominantly Inherited Alzheimer's Network (DIAN Project) (AV ADAD)

Alzheimer Disease

United States
Tammie L. S. Benzinger, MD, PhD

Completed

F 18 T807 Tau PET Imaging of Progressive Posterior Cortical Dysfunction (IND 123119, Protocol E) (Protocol E)

Alzheimer Disease | Progressive Posterior Cortical Dysfunction (PPCD)

United States
Avid Radiopharmaceuticals

Withdrawn

18F-AV-1451 PET Imaging in TBI

Traumatic Brain Injury

United States
Tammie L. S. Benzinger, MD, PhD

Completed

F 18 T807 PET (Positron Emission Tomograph )Scan for HIV Infected & Uninfected

Alzheimer Disease | HIV

United States
Cellxpert Biotechnology Corp.
Medigen Biotechnology Corporation

Completed

PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma

Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

Australia, United States
Avid Radiopharmaceuticals

Terminated

Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Alzheimer's Disease

United States
Avid Radiopharmaceuticals

Completed

Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.

Frontotemporal Dementia | Alzheimer's Disease

United Kingdom
Tammie L. S. Benzinger, MD, PhD

Withdrawn

F 18 T807 Tau PET Imaging of Frontotemporal Dementia (FTD)

Alzheimer Disease

United States
Avid Radiopharmaceuticals

Completed

18F-AV-1451 High Resolution Autopsy Study

Alzheimer's Disease

United States

Search clinical trials for: [18F]PI-2620

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations